Treatment outcomes of recombinant human granulocyte macrophage colony stimulating factor in a model mouse with sepsis
Feng Min
Chang Si-yuan
Xu Da-qian
Liu Gang
Abstract：BACKGROUND:Granulocyte colony-stimulating factor has been shown to be used for the treatment of granulocytopenia, but its effect on sepsis is little reported. <br> OBJECTIVE:To explore the treatment outcomes of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) for sepsis mice. <br> METHODS:A sepsis mouse model was established by intraperitoneal injection of lipopolysaccharide, and then given subcutaneous injection of rhGM-CSF at 6 and 30 hours after modeling. The morphological change of mouse lung tissue, CD64 expression in peripheral neutrophils, and serum levels of tumor necrosis factor-αand interleukin-10 were ovserved, respectively. <br> RESULTS AND CONCLUISON:(1) Complete bronchial epithelial, mild stromal hyperplasia, and a few neutrophil infiltration were found after rhGM-CSF treatment. (2) CD64 expression in peripheral neutrophils, and serum level of interleukin-10 in the treatment group were significantly higher than those in the model and control groups at 1, 3 and 7 days after treatment (P<0.05). The serum level of tumor necrosis factor-αin the treatment group was significantly higher than that in the control group, but lower than that in the model group after 1, 3 and 7 days of treatment (P<0.05). (4) These results show that rhGM-CSF can enhance neutrophil function and the anti-inflammatory effects in sepsis mice.
Machine-generated Keywords：
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 7391-7396 )